Research areas and methodologies
The Complex Hematology and Stem Cell Transplant Operational Unit carries out clinical-assistance activities for the diagnosis and treatment of diseases of the blood and the organs that produce it. In particular, it follows patients with blood diseases of both a neoplastic nature (leukemia, lymphoma, myeloma) and non-neoplastic nature (anaemia, thrombocytopenia, acquired coagulopathies, hereditary and/or acquired thrombophilias, etc.). She specializes in the prevention of multiple miscarriages due to hematological causes. The Hematology Operational Unit is accredited by the organization JACIE (Joint Accreditation Committee – ISCT & EBMT), which guarantees international quality and safety standards for stem cell transplants.
In the field of neoplastic blood diseases and assistance to patients candidates for autologous hematopoietic stem cell transplantation, the Unit adheres to the Rome Transplant Network (RTN). RTN is a network made up of six hematology centers of excellence in Rome and carries out stem cell transplants according to common protocols, certified by international bodies, from National Transplant Center (CNT) and since National Blood Center (CNS). Each center specializes in a certain area of their application. Within the RTN, the Hematology Operational Unit of the Campus Bio-Medico University Hospital, in collaboration with the Urology, is implementing advanced experimental cycles for the treatment of post-transplant hemorrhagic cystitis through endoscopic application of fibrin glue.
Structure of excellence for the treatment of myeloma, lymphoma and leukemia, the Operating Unit is an active member of numerous national cooperative groups (GIMEMA , FIL,) and international (IELSG,EMN) and applies protocols of chemotherapy, cell therapy, radiotherapy and biological therapies, proposed by these cooperative groups, and which stimulate the immune system to recognize and destroy neoplastic cells.
Actively participates in regional pathology groups.
The Operating Unit has also drawn up the PDTA for patients suffering from Castleman's Disease, coordinated by Dr. Ombretta Annibali.
The research unit in collaboration with the Pathological Anatomy Unit is conducting studies on new immunoassays such as TIGIT in Hodgkin's lymphoma and multiple myeloma. TIGIT is a new immunocheckpoint that negatively regulates T cell function and shows encouraging data for the use of new molecules in resistant patients.
Collaborations with other Research Centers
- European Group for Blood and Marrow Transplantation (EBMT), Leiden (Netherlands)
- Federation of Centers for the Diagnosis of Thrombosis and the Surveillance of Antithrombotic Therapies (FCSA), Milan
- The Italian Study Group for Amyloidosis (SIA)
- Italian Lymphoma Foundation (FIL), Alessandria
- Italian Group of Hematological Diseases of Adults (GIMEMA), Rome
- Italian Group for Bone Marrow Transplantation (GITMO), Genoa
- International Extranodal Lymphoma Study Group (IELSG), Bellinzona (Switzerland)
- Joint Accreditation Committee ISCT-EBMT (JACIE), Barcelona (Spain)
- Rome Transplant Network (RTN), Rome
- European Myeloma Network Foundation, Italy (EMN), Turin
The Research Unit benefits from the support of the following WORKSHOPS:
- Level I hematology laboratory for the cytomorphological diagnosis of blood pathologies on peripheral blood and bone marrow;
- Cytofluorimetry laboratory for cellular immunophenotypic characterization;
- Laboratory of Haemostasis and Thrombosis and monitoring of Oral Anticoagulant Treatment (TAO), affiliated to the FCSA (Federation of Centers for the diagnosis of thrombosis and the Surveillance of Antithrombotic therapies);
- Minimal cell manipulation laboratory for autologous hematopoietic stem cell transplantation within the RTN Metropolitan Transplant Network, for non-advanced cell therapy with bone marrow progenitors, and for cell regeneration therapies using blood components for non-transfusion use.